Effectiveness and durability of COVID-19 vaccination in 9447 patients with IBD: a systematic review and meta-analysis

A Jena, D James, AK Singh, U Dutta… - Clinical …, 2022 - Elsevier
Background And Aims The serological responses after severe acute respiratory syndrome
coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study …

Immunizing the imperfect immune system: Coronavirus disease 2019 vaccination in patients with inborn errors of immunity

JR Durkee-Shock, MD Keller - Annals of Allergy, Asthma & Immunology, 2022 - Elsevier
Objective To update clinicians on current evidence regarding the immunogenicity and safety
of coronavirus disease 2019 (COVID-19) vaccines in patients with inborn errors of immunity …

A global federated real-world data and analytics platform for research

MB Palchuk, JW London, D Perez-Rey, ZJ Drebert… - JAMIA …, 2023 - academic.oup.com
Objective This article describes a scalable, performant, sustainable global network of
electronic health record data for biomedical and clinical research. Materials and Methods …

Impact of SARS-CoV-2 vaccination on inflammatory bowel disease activity and development of vaccine-related adverse events: results from PREVENT-COVID

KN Weaver, X Zhang, X Dai, R Watkins… - Inflammatory bowel …, 2022 - academic.oup.com
Background Severe acute respiratory syndrome coronavirus 2 vaccination is recommended
for all individuals with inflammatory bowel disease (IBD), including those on …

COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation

R Lev-Tzion, G Focht, R Lujan, A Mendelovici… - Clinical …, 2022 - Elsevier
Background & Aims Studies have shown decreased response to coronavirus disease 2019
(COVID-19) vaccinations in some populations. In addition, it is possible that vaccine …

Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 …

J Widdifield, JC Kwong, S Chen, L Eder… - The Lancet …, 2022 - thelancet.com
Background We estimated COVID-19 vaccine effectiveness against SARS-CoV-2 infection
and severe COVID-19 outcomes among individuals with immune-mediated inflammatory …

Adalimumab and infliximab impair SARS-CoV-2 antibody responses: results from a therapeutic drug monitoring study in 11 422 biologic-treated patients

N Chanchlani, S Lin, D Chee, B Hamilton… - Journal of Crohn's …, 2022 - academic.oup.com
Abstract Background and Aims Infliximab attenuates serological responses to SARS-CoV-2
infection. Whether this is a class effect, or if anti-tumour necrosis factor [anti-TNF] level …

[HTML][HTML] Ulcerative colitis: rapid evidence review

SM Adams, ED Close, AP Shreenath - American Family Physician, 2022 - aafp.org
Ulcerative colitis is a relapsing and remitting inflammatory bowel disease of the large
intestine. Risk factors include recent Salmonella or Campylobacter infection and a family …

Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic

S Lin, LHS Lau, N Chanchlani, NA Kennedy, SC Ng - Gut, 2022 - gut.bmj.com
The COVID-19 pandemic has raised considerable concerns that patients with inflammatory
bowel disease (IBD), particularly those treated with immunosuppressive therapies, may …

Effectiveness and safety of SARS‐CoV‐2 vaccine in inflammatory bowel disease patients: a systematic review, meta‐analysis and meta‐regression

A Bhurwal, H Mutneja, V Bansal, A Goel… - Alimentary …, 2022 - Wiley Online Library
Introduction There are concerns regarding the effectiveness and safety of SARS‐CoV‐2
vaccine in inflammatory Bowel Disease (IBD) patients. This systematic review and meta …